HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal

Class

Fixed-dose combination: statin (HMG-CoA reductase inhibitor) + cholesterol absorption inhibitor

Pathway

Rosuvastatin inhibits hepatic cholesterol biosynthesis, upregulating LDL receptors; ezetimibe blocks NPC1L1-mediated intestinal cholesterol absorption — complementary LDL-C lowering

Notes

original target text: HMG-CoA reductase (rosuvastatin component) + NPC1L1 intestinal cholesterol transporter (ezetimibe component)

LDL cholesterol drives atherosclerotic cardiovascular disease, and lowering it is a central strategy for reducing cardiovascular risk. This fixed-dose combination reduces LDL-C through two complementary mechanisms acting on different organs. The statin component inhibits HMG-CoA reductase, the rate-limiting enzyme of the liver's mevalonate pathway that synthesizes cholesterol. Reduced hepatic cholesterol synthesis prompts liver cells to increase surface LDL receptors, which pull more LDL particles out of the bloodstream. The second component blocks NPC1L1, a transporter on intestinal cells responsible for absorbing dietary and bile-derived cholesterol. Blocking it reduces the amount of cholesterol delivered to the liver from the gut. Because the liver senses less incoming cholesterol from this route, it further increases LDL receptor expression, reinforcing the statin's effect. Pairing a hepatic-synthesis inhibitor with an intestinal-absorption inhibitor exploits two distinct cholesterol sources simultaneously, achieving greater LDL-C lowering than either mechanism alone at comparable doses. This dual-pathway approach can also permit a lower statin dose while still reaching target LDL-C, which matters for patients who are sensitive to statin-related side effects. Such combinations are used broadly across primary and secondary prevention of atherosclerotic cardiovascular disease, particularly when statin monotherapy alone does not achieve sufficient LDL-C reduction.